Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

The oncology apoptosis modulators market, valued at USD 3.9 billion in 2022, is poised for significant growth, with ...

A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...

Researchers at Helmholtz Munich, in collaboration with colleagues at Tohoku University, have identified a specific redox protein as a critical regulator of ferroptosis - a form of regulated oxidative ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

A recent study unveiled a key enzyme involved in producing selenoproteins, opening new strategies for treating certain types of cancer in children.

Programmed Cell Death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies called checkpoint ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Gotistobart is a next-generation anti-cytotoxic T-lymphocyte-associated protein 4 antibody candidate ... despite prior treatment with a programmed cell death protein 1 or programmed death ligand ...